These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
17. Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Berek JS; Hacker NF; Lichtenstein A; Jung T; Spina C; Knox RM; Brady J; Greene T; Ettinger LM; Lagasse LD Cancer Res; 1985 Sep; 45(9):4447-53. PubMed ID: 4028027 [TBL] [Abstract][Full Text] [Related]
18. Biological response modifiers for the therapy of cancer. Herberman RB Ann Allergy; 1985 May; 54(5):376-80. PubMed ID: 3994067 [TBL] [Abstract][Full Text] [Related]
19. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180 [TBL] [Abstract][Full Text] [Related]
20. Bio-immunotherapy for cancer in experimental studies and clinical application: current status and future challenges. Shen RN; Lu L; Kaiser HE; Broxmeyer HE In Vivo; 1994; 8(5):643-52. PubMed ID: 7727711 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]